Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer

Published:April 08, 2013DOI:https://doi.org/10.1016/j.ejon.2013.02.004

      Abstract

      Introduction

      Cytotoxic therapy for patients with cancer frequently induces reversible, but long-lasting alopecia which might be prevented by scalp cooling. This study evaluates the effectiveness of scalp cooling with respect to the severity of chemotherapy-induced alopecia (CIA) and the purchase and use of wigs and head covers.

      Materials and methods

      In this observational study, scalp-cooled patients (n = 160) were compared with non scalp-cooled patients (n = 86) with several types of cancer. Patients were enrolled in 15, mostly general hospitals prior to taxane and/or anthracycline-based chemotherapy. Patients completed four questionnaires between the start and one year after the last chemotherapy.

      Results

      Severity of CIA, and purchasing and actually wearing wigs and head covers were significantly lower among scalp-cooled than non scalp-cooled patients. Overall, scalp cooling reduced the use of wigs and head covers by 40%. Among 84 scalp-cooled patients who purchased a wig (53%), only 52 patients actually wore it (62%), and they just wore it intensively (86% daily) for less than six months (80%). Especially young patients camouflaged CIA with a head cover instead of a wig.

      Discussion

      The relatively long duration of CIA, the wish of many patients to camouflage or rather prevent it and the 40% reduction for head covering by scalp cooling, makes it a worthwhile supportive intervention. However, (cost-) effectiveness can be improved. Many scalp-cooled patients purchased a wig unnecessarily.

      Keywords

      To read this article in full you will need to make a payment

      References

        • Auvinen P.K.
        • Mahonen U.A.
        • Soininen K.M.
        • Paananen P.K.
        • Ranta-Koponen P.H.
        • Saavalainen I.E.
        • et al.
        The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia.
        Tumori. 2010; 96: 271-275
        • Batchelor D.
        Hair and cancer chemotherapy: consequences and nursing care – a literature study.
        European Journal of Cancer Care. 2001; 10: 147-163
        • Breed W.P.M.
        • Hurk van den C.J.G.
        • Peerbooms M.
        Presentation, impact and prevention of chemotherapy-induced hair loss; scalp cooling potentials and limitations.
        Expert Review Dermatology. 2011; 6: 109-125
      1. Can, G., Demir, M., Erol, O., Aydiner, A. A comparison of men and women's experiences of chemotherapy-induced alopecia. European Journal of Oncology Nursing, in press.

        • Cohen B.
        The cross-section trichometer: a new device for measuring hair quantity, hair loss, and hair growth.
        Dermatologic Surgery. 2008; 34: 900-910
        • Cotsarelis G.
        • Millar S.E.
        Towards a molecular understanding of hair loss and its treatment.
        Trends in Molecular Medicine. 2001; 7: 293-301
        • Dean J.C.
        • Salmon S.E.
        • Griffith K.S.
        Prevention of doxorubicin-induced hair loss with scalp hypothermia.
        The New England Journal of Medicine. 1979; 301: 1427-1429
        • Frith H.
        • Harcourt D.
        • Fussell A.
        Anticipating an altered appearance: women undergoing chemotherapy treatment for breast cancer.
        European Journal of Oncology Nursing. 2007; 11: 385-391
        • Grevelman E.G.
        • Breed W.P.
        Prevention of chemotherapy-induced hair loss by scalp cooling.
        Annals of Oncology. 2005; 16: 352-358
      2. Hendriks, M.A.E., Geerts, P.A.F., Dercksen, P.A.F., van den Hurk, C.J.G., Breed, W.P.M. The usefulness of Cohen's cross-section trichometer for measuring hair quantity. Dermatologic Surgery, in press.

        • Hilton S.
        • Hunt K.
        • Emslie C.
        • Salinas M.
        • Ziebland S.
        Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia.
        Psycho-oncology. 2008; 17 (11 November 2012): 577-583
        • Hurk van den C.J.
        • Breed W.P.
        • Nortier J.W.
        Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia.
        Supportive Care in Cancer. 2012; 20: 3255-3260
        • Hurk van den C.J.
        • Mols F.
        • Vingerhoets A.J.
        • Breed W.P.
        Impact of alopecia and scalp cooling on the well-being of breast cancer patients.
        Psycho-oncology. 2010; 19: 701-709
        • Hurk van den C.J.
        • Peerbooms M.
        • van de Poll-Franse L.V.
        • Nortier J.W.
        • Coebergh J.W.
        • Breed W.P.
        Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients – results of the Dutch Scalp Cooling Registry.
        Acta Oncologica (Stockholm, Sweden). 2012; 51: 497-504
        • McGarvey E.L.
        • Baum L.D.
        • Pinkerton R.C.
        • Rogers L.M.
        Psychological sequelae and alopecia among women with cancer.
        Cancer Practice. 2001; 9: 283-293
        • Mols F.
        • van den Hurk C.J.
        • Vingerhoets A.J.
        • Breed W.P.
        Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations.
        Supportive Care in Cancer. 2009; 17: 181-189
        • Mulders M.
        • Vingerhoets A.
        • Breed W.
        The impact of cancer and chemotherapy: perceptual similarities and differences between cancer patients, nurses and physicians.
        European Journal of Oncology Nursing. 2008; 12: 97-102
        • Oncoline
        Guideline Mamma Carcinoma 2012.
        (Richtlijn Mammacarcinoom 2012) Comprehensive Cancer Centre, The Netherlands, Utrecht2012
        • Protiere C.
        • Evans K.
        • Camerlo J.
        • d'Ingrado M.P.
        • Macquart-Moulin G.
        • Viens P.
        • et al.
        Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy.
        Supportive Care in Cancer. 2002; 10: 529-537
        • Rosman S.
        Cancer and stigma: experience of patients with chemotherapy-induced alopecia.
        Patient Education and Counseling. 2004; 52: 333-339
        • Tighe M.
        • Molassiotis A.
        • Morris J.
        • Richardson J.
        Coping, meaning and symptom experience: a narrative approach to the overwhelming impacts of breast cancer in the first year following diagnosis.
        European Journal of Oncology Nursing. 2011; 15: 226-232
        • Trueb R.M.
        Chemotherapy-induced alopecia.
        Seminars in Cutaneous Medicine and Surgery. 2009; 28: 11-14
        • Williams J.
        • Wood C.
        • Cunningham-Warburton P.
        A narrative study of chemotherapy-induced alopecia.
        Oncology Nursing Forum. 1999; 26: 1463-1468
        • World Health Organisation
        Handbook for Reporting Results of Cancer Treatment.
        WHO Offset Publ., Geneva1979
        • Zannini L.
        • Verderame F.
        • Cucchiara G.
        • Zinna B.
        • Alba A.
        • Ferrara M.
        ‘My wig has been my journey's companion’: perceived effects of an aesthetic care programme for Italian women suffering from chemotherapy-induced alopecia.
        European Journal of Cancer Care. 2012; 21: 650-660